Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Moore, Andrew R ^a   Boyce, Malcolm ^b   Steele, Islay A ^a   Campbell, Fiona ^c   Varro, Andrea ^a   Pritchard, D Mark ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Hammersmith Medicines Research Limited and Trio Medicines Limited   (United Kingdom)

^c ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; GASTRIN; HISTIDINE DECARBOXYLASE; MATRILYSIN; NETAZEPIDE; TUMOR MARKER;

ACHLORHYDRIA; ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CELL COUNT; CHRONIC DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; GASTRIC NEUROENDOCRINE TUMOR; GASTRIC NEUROENDOCRINE TUMOR TYPE I; GASTRIN BLOOD LEVEL; GASTROINTESTINAL BIOPSY; GASTROSCOPY; HUMAN; HUMAN CELL; MALE; MORNING DOSAGE; MULTIPLE CANCER; NEUROENDOCRINE TUMOR; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; STOMACH TUMOR; TUMOR REGRESSION; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; BIOLOGICAL MARKERS; BIOPSY; CHROMOGRANIN A; FEMALE; GASTRIC MUCOSA; GASTRINS; GASTRITIS, ATROPHIC; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PHENYLUREA COMPOUNDS; RECEPTOR, CHOLECYSTOKININ B; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84885077371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076462     Document Type: Article

References (59)

1. Burkitt MD, Pritchard DM, (2006) Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 24: 1305-1320. doi:10.1111/j.1365-2036.2006.03130.x. PubMed: 17059512.
2. Modlin I, Lye K, Kidd M, (2004): pp. A50year analysis of 562 gastric carcinoids: small tumour or larger problem? Ann J Gastroenterol 99: 23-32.
3. Hodgson N, Koniaris LG, Livingstone AS, Franceschi D, (2005) Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 19: 1610-1612. doi:10.1007/s00464-005-0232-4. PubMed: 16211437.
4. Ellis L, Shale MJ, Coleman MP, (2010) Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 105: 2563-2569. doi:10.1038/ajg.2010.341. PubMed: 20823835.
5. Scherübl H, Cadiot G, Jensen RT, Rösch T, Stölzel U, et al. (2010) Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 42: 664-671. doi:10.1055/s-0030-1255564. PubMed: 20669078.
6. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning E, et al. (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinol 80: 394-424. doi:10.1159/000085237.
7. Salazar R, Wiedenmann B, Rindi G, (2012) ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinol 95: 71-73. doi:10.1159/000335600. PubMed: 22262042.
8. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, et al. (2010) North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39: 735-752. doi:10.1097/MPA.0b013e3181ebb168. PubMed: 20664472.
9. Higashino K, Iishi H, Narahara H, Uedo N, Yano H, et al. (2004) Endoscopic resection with a two-channel videoendoscope for gastric carcinoid tumors. Hepatogastroenterology 51: 269-272. PubMed: 15011883.
10. Hopper AD, Bourke MJ, Hourigan LF, Tran K, Moss A, et al. (2009) En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multi-band mucosectomy. J Gastroenterol Hepatol 24: 1516-1521. doi:10.1111/j.1440-1746.2009.05909.x. PubMed: 19743997.
11. Merola E, Sbrozzi-Vanni A, Panzuto F, D'Ambra G, Giulio, Di Eet al (2012) Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinol 95: 207-213. doi:10.1159/000329043. PubMed: 21811050.
12. Eckhauser FE, Lloyd RV, Thompson NW, Raper SE, Vinik AI, (1988) Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery 104: 1046-1053. PubMed: 3194832.
13. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW, (1992) Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 102: 1409-1418. PubMed: 1551550.
14. Borch K, Ahrén B, Ahlman H, Falkmer S, Granérus G, et al. (2005) Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242: 64-73. doi:10.1097/01.sla.0000167862.52309.7d. PubMed: 15973103.
15. Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB, (2006) Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 93: 368-72. PubMed: 16550587.
16. Hoshino M, Omura N, Yano F, Tsuboi K, Matsumoto A, et al. (2010) Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia. Hepatogastroenterology 57: 379-382. PubMed: 20583448.
17. Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM, (2010) Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res 162: 22-25. doi:10.1016/j.jss.2010.01.005. PubMed: 20421108.
18. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, et al. (2004) Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 39: 621-628. doi:10.1080/00365520410005225. PubMed: 15370681.
19. Khuroo MS, Khuroo MS, Khuroo NS, (2010) Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. J Gastroenterol Hepatol 25: 548-554. doi:10.1111/j.1440-1746.2009.06131.x. PubMed: 20074162.
20. Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, et al. (2008) Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 159: 475-482. doi:10.1530/EJE-08-0420. PubMed: 18662970.
21. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, et al. (2008) Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 15: 337-342. doi:10.1677/ERC-07-0251. PubMed: 18310299.
22. Sanduleanu S, De Bruïne A, Stridsberg M, Jonkers D, Biemond I, et al. (2001) Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 31: 802-811. doi:10.1046/j.1365-2362.2001.00890.x. PubMed: 11589723.
23. Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, et al. (2005) Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 152: 443-448. doi:10.1530/eje.1.01862. PubMed: 15757862.
24. Jianu CS, Fossmark R, Syversen U, Hauso Ø, Waldum HL, (2010) A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia. Tumour Biol 31: 373-380. doi:10.1007/s13277-010-0045-5. PubMed: 20480408.
25. Plöckinger U, Dienemann D, Quabbe HJ, (1990) Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 71: 1658-1662. doi:10.1210/jcem-71-6-1658. PubMed: 2229321.
26. Dockray GJ, Varro A, Dimaline R, Wang T, (2001) The gastrins: their production and biological activities. Annu Rev Physiol 63: 119-139. doi:10.1146/annurev.physiol.63.1.119. PubMed: 11181951.
27. Black JW, Kalindjian SB, (2002) Gastrin agonists and antagonists. Pharmacol Toxicol 91: 275-281. doi:10.1034/j.1600-0773.2002.910602.x. PubMed: 12688368.
28. Herranz R, (2003) Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 23: 559-605. doi:10.1002/med.10042. PubMed: 12789687.
29. Berna MJ, Jensen RT, (2007) Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem 7: 1211-1231. doi:10.2174/156802607780960519. PubMed: 17584143.
30. Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, et al. (1997) (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J Med Chem 3140:: 331-341. PubMed: 9022799.
31. Takinami Y, Yuki H, Nishida A, Akuzawa S, Uchida A, et al. (1997) YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther 11: 113-120. doi:10.1046/j.1365-2036.1997.110281000.x. PubMed: 9042983.
32. Takemoto Y, Yuki H, Nishida A, Ito H, Kobayashi-Uchida A, et al. (1998) Effects of YF476, a potent and selective gastrin/CCK-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula. Arzneim Forsch 48: 403-407.
33. Kitano M, Norlén P, Ding X-Q, Nakamura S, Håkanson R, (2000) Long-lasting CCK2 receptor blockade after a single subcutaneous injection of YF476 or YM022. Br J Pharmacol 130: 699-705. doi:10.1038/sj.bjp.0703342. PubMed: 10821801.
34. Martinsen TC, Kawase S, Håkanson R, Torp SH, Fossmark R, et al. (2003) Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis 24: 1887-1896. doi:10.1093/carcin/bgg156. PubMed: 12949047.
35. Kidd M, Siddique ZL, Drozdov I, Gustafsson BI, Camp RL, et al. (2010) The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul Pept 162: 52-60. doi:10.1016/j.regpep.2010.01.009. PubMed: 20144901.
36. Cui G, Takaishi S, Ai W, Betz KS, Florholmen J, et al. (2006) Gastrin-induced apoptosis contributes to carcinogenesis in the stomach. Lab Invest 86: 1037-1051. doi:10.1038/labinvest.3700462. PubMed: 16894354.
37. Takaishi S, Cui G, Frederick DM, Carlson JE, Houghton J, et al. (2005) Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 128: 1965-1983. doi:10.1053/j.gastro.2005.03.027. PubMed: 15940630.
38. Boyce M, David O, Darwin K, Mitchell T, Johnston A, et al. (2012) Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther 36: 181-189. doi:10.1111/j.1365-2036.2012.05143.x. PubMed: 22607579.
39. Boyce M, Warrington S, (2013) Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24-h gastric acidity and gastrin in healthy subjects. Br J Clin Pharmacol (. (2013)) PubMed: 23432415.
40. Boyce M, Warrington S, Black J, (2013) Netazepide, a gastrin/CCK(2) receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. Br J Clin Pharmacol (. (2013)) PubMed: 23432534.
41. Investigator's brochure for netazepide. Trio Medicines (December(2011).
42. Nørsett KG, Steele I, Duval C, Murugesan SV, Kenny S, et al. (2011) Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 301: G446-G453. doi:10.1152/ajpgi.00527.2010. PubMed: 21193525.
43. Kenny S, Duval C, Sammut SJ, Steele I, Pritchard DM, et al. (2008) Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 295: G431-G441. doi:10.1152/ajpgi.90283.2008. PubMed: 18599586.
44. Varro A, Kenny S, Hemers E, McCaig C, Przemeck S, et al. (2007) Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling. Am J Physiol Gastrointest Liver Physiol 292: G1133-G1140. PubMed: 17218472.
45. Varro A, Hemers E, Archer D, Pagliocca A, Haigh C, et al. (2002) Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin. Gastroenterology 123: 271-280. doi:10.1053/gast.2002.34162. PubMed: 12105855.
46. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, et al. (1988) Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41: 185-200. doi:10.1159/000199786. PubMed: 3072229.
47. Dockray GJ, (1980) Immunochemical studies on big gastrin using NH2-terminal specific antisera. Regul Pept 1: 169-186. doi:10.1016/0167-0115(80)90270-0. PubMed: 6165051.
48. Varro A, Ardill JE, (2003) Gastrin: an analytical review. Ann Clin Biochem 40: 472-480. doi:10.1258/000456303322326380. PubMed: 14503984.
49. Redrup M, Leaf F, Miyashita A, Watanbi T, Huguchi S, et al. (2002) Validation of a liquid chromatographic-tandem mass spectrometric method for the measurement of (R)-1-[2,3- dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3methylaminophenyl)urea (YF476) in human plasma. J Chromatogr 772: 317-325.
50. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, et al. (2007) Chromogranin A: Is it a useful marker of neuroendocrine tumors? J Clin Oncol 25: 1967-1973. doi:10.1200/JCO.2006.10.1535. PubMed: 17513802.
51. Higham AD, Dimaline R, Varro A, Attwood S, Armstrong G, et al. (1998) Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumour. Gastroenterology 114: 817-822. doi:10.1016/S0016-5085(98)83330-1. PubMed: 9516403.
52. Murugesan SV, Steele IA, Dimaline R, Poston GJ, Shrotri M, et al. (2013) Correlation between short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours. Eur J Gastroenterol Hepatol 25: 474-481. PubMed: 23249603.
53. Derendorf H, VanderMaelen CP, Brickl RS, Eisert W, (2005) Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol 45: 845-850. doi:10.1177/0091270005276738. PubMed: 15951475.
54. Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE, (1993) Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 7: 317-321. PubMed: 8117350.
55. Rehfeld JF, Gingras MH, Bardram L, Hilsted L, Goetze JP, et al. (2011) The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 140: 1444-1453. doi:10.1053/j.gastro.2011.01.051. PubMed: 21315717.
56. Rehfeld JF, Bardram L, Hilsted L, Poitras P, Goetze JP, (2012) Pitfalls in diagnostic gastrin measurements. Clin Chem 58: 831-836. doi:10.1373/clinchem.2011.179929. PubMed: 22419747.
57. Fossmark R, Sørdal O, Jianu CS, Qvigstad G, Nordrum IS, et al. (2012) Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 36: 1067-1075. doi:10.1111/apt.12090. PubMed: 23072686.
58. Commission European, Website. Designation EU/3/07/. Available: http://ec.europa.eu/health/documents/community-register/html/orphreg.htm. (Accessed 2013 August 31).
59. Food US, & Drug Administration Website. Designation 07-2432. Available: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=243207. (Accessed 2013 August 31).